AU2001245741A1 - Antisense inhibition of adam10 expression - Google Patents
Antisense inhibition of adam10 expressionInfo
- Publication number
- AU2001245741A1 AU2001245741A1 AU2001245741A AU4574101A AU2001245741A1 AU 2001245741 A1 AU2001245741 A1 AU 2001245741A1 AU 2001245741 A AU2001245741 A AU 2001245741A AU 4574101 A AU4574101 A AU 4574101A AU 2001245741 A1 AU2001245741 A1 AU 2001245741A1
- Authority
- AU
- Australia
- Prior art keywords
- antisense inhibition
- adam10 expression
- adam10
- expression
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/527,154 US6228648B1 (en) | 2000-03-17 | 2000-03-17 | Antisense modulation of ADAM10 expression |
| US09527154 | 2000-03-17 | ||
| PCT/US2001/008259 WO2001071008A1 (en) | 2000-03-17 | 2001-03-15 | Antisense inhibition of adam10 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001245741A1 true AU2001245741A1 (en) | 2001-10-03 |
Family
ID=24100317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001245741A Abandoned AU2001245741A1 (en) | 2000-03-17 | 2001-03-15 | Antisense inhibition of adam10 expression |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US6228648B1 (en) |
| AU (1) | AU2001245741A1 (en) |
| WO (1) | WO2001071008A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040043928A1 (en) * | 2001-08-02 | 2004-03-04 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
| US20080139512A1 (en) * | 2002-09-25 | 2008-06-12 | Quick-Med Technologies, Inc. | Method for minimizing or avoiding adverse effects of vesicants |
| EP1623995A1 (en) * | 2004-08-06 | 2006-02-08 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibitors of L1 and ADAM10 for the treatment of carcinomas |
| US8210051B2 (en) * | 2004-12-03 | 2012-07-03 | General Electric Company | System and method for cyclic testing |
| US7353715B2 (en) * | 2004-12-03 | 2008-04-08 | General Electric Company | System, apparatus and method for testing under applied and reduced loads |
| US8210050B2 (en) * | 2004-12-03 | 2012-07-03 | General Electric Company | Apparatus and system for cyclic testing |
| EP1984500A2 (en) * | 2006-01-13 | 2008-10-29 | Vanderbilt University | Adam10 and its uses related to infection |
| EP2197497B1 (en) | 2007-09-27 | 2016-06-01 | ImmunoVaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
| AU2009253780B2 (en) | 2008-06-05 | 2014-08-14 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| CN113876945A (en) | 2011-10-06 | 2022-01-04 | 免疫疫苗技术有限公司 | Liposome composition comprising adjuvant for activating or increasing TLR2 activity and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5922546A (en) * | 1997-08-25 | 1999-07-13 | Smithkline Beecham Corporation | Human disintegrin metalloprotease KUZ gene |
-
2000
- 2000-03-17 US US09/527,154 patent/US6228648B1/en not_active Expired - Fee Related
-
2001
- 2001-03-15 US US10/221,643 patent/US20030211610A1/en not_active Abandoned
- 2001-03-15 AU AU2001245741A patent/AU2001245741A1/en not_active Abandoned
- 2001-03-15 WO PCT/US2001/008259 patent/WO2001071008A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US6228648B1 (en) | 2001-05-08 |
| US20030211610A1 (en) | 2003-11-13 |
| WO2001071008A1 (en) | 2001-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001229493A1 (en) | Antisense modulation of mekk2 expression | |
| AU2002213002A1 (en) | Antisense inhibition of caspase 6 expression | |
| AU2001289085A1 (en) | Antisense modulation of flip-c expression | |
| AU2002227435A1 (en) | Antisense modulation of calreticulin expression | |
| AU2002253836A1 (en) | Aptamer-mediated regulation of gene expression | |
| AU6111000A (en) | Inhibitors of viral helcase | |
| AU2001277003A1 (en) | Antisense inhibition of her-3 expression | |
| AU1488501A (en) | Methods of inhibiting metastasis | |
| AU2001227847A1 (en) | Antisense modulation of pepck-cytosolic expression | |
| AU2001245741A1 (en) | Antisense inhibition of adam10 expression | |
| AU2001283443A1 (en) | Antisense modulation of hpk/gck-like kinase expression | |
| AU2001257220A1 (en) | Antisense modulation of inhibitor of dna binding-1 expression | |
| AU4369000A (en) | Inhibition of complement action | |
| AU2001288968A1 (en) | Antisense modulation of btak expression | |
| AU2002226064A1 (en) | Antisense modulation of talin expression | |
| AUPQ629000A0 (en) | Inhibition of fungi | |
| AU2001252884A1 (en) | Method of dopamine inhibition using l-threo-methylphenidate | |
| AU2002214038A1 (en) | Inhibitors of transglutaminases | |
| AU2001234462A1 (en) | Antisense modulation of cot oncogene expression | |
| AU2001287136A1 (en) | Antisense modulation of glioma-associated oncogene-1 expression | |
| AU2003239864A1 (en) | Antisense moodulation of kinesin-like 1 expression | |
| AU2001292947A1 (en) | Methods for inhibition of viral infection | |
| AU2001234461A1 (en) | Antisense modulation of daxx expression | |
| AU2001288908A1 (en) | Antisense modulation of mekk3 expression | |
| AU2001288907A1 (en) | Antisense modulation of a20 expression |